Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2020-11-16 M&A Activity
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Karo Pharma AB divests its Hospital Supply business, Swereco AB, to J2L Holding AB
M&A Activity Classification · 99% confidence The document is a press release announcing the divestment of a business unit (Swereco AB) by Karo Pharma AB to J2L Holding AB. It details the strategic rationale, the financial terms (SEK 150 million), and the closing date (December 1st, 2020). This type of announcement, concerning a significant corporate transaction like a divestiture, falls under the category of M&A Activity (TAR). Although it is a formal announcement, its content is specific to a merger/acquisition/divestiture event, making TAR more precise than a general Regulatory Filing (RNS). The document length is short (3445 chars), but the content is the primary announcement itself, not just a notice that a report is attached, thus it is not an RPA.
2020-11-16 English
Karo Pharma AB avyttrar Hospital Supply-verksamheten, Swereco AB, till J2L Holding AB
Regulatory Filings Classification · 100% confidence The document is a press release from Karo Pharma AB announcing the divestiture (sale) of its Hospital Supply business unit, Swereco AB, to J2L Holding AB for 150 MSEK. It details the strategic rationale, the financial impact (118 MSEK in 2019 revenue), and the closing date (December 1, 2020). The text concludes with a statement that the information is required to be made public under EU's Market Abuse Regulation and provides contact information. This type of announcement, detailing a significant corporate transaction like a sale of a business unit, is best classified as a general corporate action or regulatory filing. Since there is no specific category for 'Divestiture Announcement' and it is not a standard financial report (10-K, IR, ER), it falls under the general regulatory announcement category, RNS, or potentially TAR (Merger/Acquisition Activity), although TAR usually implies a takeover bid or merger, not a simple divestiture. Given the context of mandatory disclosure under market abuse rules, RNS (Regulatory Filings) is the most appropriate general classification for this type of material corporate event announcement that isn't a core financial report or management discussion.
2020-11-16 Swedish
Earnings Release 2020
Earnings Release Classification · 99% confidence The document is titled 'Karo Pharma publicerar rapport för tredje kvartalet 2020...' (Karo Pharma publishes report for the third quarter of 2020...). It contains detailed financial metrics (Nettoomsättning, EBIT, EBITDA, Bruttomarginal) broken down by quarter (Kv 3, juli-september) and year-to-date (januari - september). This structure is characteristic of a comprehensive financial report covering a period shorter than a full year, specifically the nine-month period ending in September (Q3). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it contains an announcement about selling own shares, the primary content is the detailed financial results for the period. Q3 2020
2020-10-30 Swedish
Earnings Release 2020
Earnings Release Classification · 100% confidence The document explicitly states in the title and throughout the text that it is the "Karo Pharma publishes third-quarter report 2020". It contains detailed financial metrics for Q3 (July - September) and the nine-month period (January - September), including Net Sales, EBIT, Adjusted EBITDA, Gross Margin, and Cash Flow. This structure and content clearly identify it as a comprehensive financial report for an interim period shorter than a full year. This matches the definition of an Interim / Quarterly Report (IR). Although it mentions a resolution on the sale of own shares, the primary focus and bulk of the document are the financial results for the period. Q3 2020
2020-10-30 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport för andra kvartalet 2020' (Report for the second quarter of 2020) for Karo Pharma. It contains detailed financial statements, including income statements, cash flow, balance sheet data, and management commentary on performance for the quarter and the first half of the year. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2020
2020-07-21 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Second-quarter report 2020' and provides comprehensive financial data, including net sales, EBIT, EBITDA, cash flow, and earnings per share for the second quarter and the first half of the year. It includes detailed financial tables, management commentary from the CEO, and analysis of business performance. As it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q2 2020
2020-07-21 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.